Business Description
![Eli Lilly and Co Eli Lilly and Co logo](https://static.gurufocus.com/logos/0C000007E3.png?14)
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Share Class Description:
WBO:LLYC: Ordinary SharesCompare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.GermanyLLY.ArgentinaLLY.Mexico1LLY.ItalyLLYC.AustriaLLY.SwitzerlandLLYCL.ChileLLY.BulgariaLLYz.UKLLY.France IPO Date
2019-06-26Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | 0.19 | |||||
Debt-to-Equity | 2.13 | |||||
Debt-to-EBITDA | 2.57 | |||||
Interest Coverage | 22.56 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 10.13 | |||||
Beneish M-Score | -1.65 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12 | |||||
3-Year EBITDA Growth Rate | -1 | |||||
3-Year EPS without NRI Growth Rate | 0.8 | |||||
3-Year Book Growth Rate | 26.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 56.94 | |||||
Future 3-5Y Total Revenue Growth Rate | 22.68 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.71 | |||||
9-Day RSI | 59.65 | |||||
14-Day RSI | 57.71 | |||||
6-1 Month Momentum % | 15.61 | |||||
12-1 Month Momentum % | 60.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.11 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 273.38 | |||||
Days Sales Outstanding | 81.94 | |||||
Days Payable | 125.76 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.55 | |||||
Dividend Payout Ratio | 0.42 | |||||
3-Year Dividend Growth Rate | 15.2 | |||||
Forward Dividend Yield % | 0.56 | |||||
5-Year Yield-on-Cost % | 1.09 | |||||
3-Year Average Share Buyback Ratio | 2 | |||||
Shareholder Yield % | -0.36 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 80.75 | |||||
Operating Margin % | 36.28 | |||||
Net Margin % | 18.86 | |||||
FCF Margin % | -9.33 | |||||
ROE % | 61.77 | |||||
ROA % | 11.75 | |||||
ROIC % | 25.06 | |||||
ROC (Joel Greenblatt) % | 67.68 | |||||
ROCE % | 24.2 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 117.33 | |||||
Forward PE Ratio | 66.79 | |||||
PE Ratio without NRI | 82.15 | |||||
Shiller PE Ratio | 170.61 | |||||
PEG Ratio | 7.68 | |||||
PS Ratio | 22.1 | |||||
PB Ratio | 63.25 | |||||
Price-to-Tangible-Book | 735.91 | |||||
Price-to-Operating-Cash-Flow | 190.55 | |||||
EV-to-EBIT | 91.87 | |||||
EV-to-Forward-EBIT | 52.26 | |||||
EV-to-EBITDA | 78.67 | |||||
EV-to-Forward-EBITDA | 46.31 | |||||
EV-to-Revenue | 22.7 | |||||
EV-to-Forward-Revenue | 19.19 | |||||
EV-to-FCF | -243.49 | |||||
Price-to-Projected-FCF | 16.61 | |||||
Price-to-Median-PS-Value | 3.84 | |||||
Price-to-Peter-Lynch-Fair-Value | 10.55 | |||||
Price-to-Graham-Number | 52.02 | |||||
Earnings Yield (Greenblatt) % | 1.09 | |||||
FCF Yield % | -0.42 | |||||
Forward Rate of Return (Yacktman) % | 8.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 36,044.117 | ||
EPS (TTM) (€) | 7.492 | ||
Beta | -0.35 | ||
Volatility % | 34.74 | ||
14-Day RSI | 57.71 | ||
14-Day ATR (€) | 22.530453 | ||
20-Day SMA (€) | 791.86 | ||
12-1 Month Momentum % | 60.83 | ||
52-Week Range (€) | 496 - 885.1 | ||
Shares Outstanding (Mil) | 900.43 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Eli Lilly and Co Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Eli Lilly and Co Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(WBO:LLYC)'s stock price today?
The current price of WBO:LLYC is €846.30. The 52 week high of WBO:LLYC is €885.10 and 52 week low is €496.00.
When is next earnings date of Eli Lilly and Co(WBO:LLYC)?
The next earnings date of Eli Lilly and Co(WBO:LLYC) is 2024-10-30.
Does Eli Lilly and Co(WBO:LLYC) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(WBO:LLYC) is 0.55% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(WBO:LLYC) was 1.96. The lowest was 0.42. And the median was 0.56. The  Forward Dividend Yield % of Eli Lilly and Co(WBO:LLYC) is 0.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |